The FDA has accepted a new drug application (NDA) for giredestrant,investigationaloralselective estrogen receptordegrader(SERD) for treatingadultpatients with estrogen receptor(ER)-positive│HER2-negative│ESR1-mutated locallyadvanc
← News
Medicine Breakthroughs Medicine Breakthroughs Health
FDA Accepts New Drug Application for Giredestrant in Advanced Breast Cancer | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Oral SERD Drug type
ER+/HER2-/ESR1-Mutant Breast Cancer Cancer type
NDA Accepted Regulatory status
Adult Patients Patient population